This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Intellectual property protections for biologic medicinals for multiple sclerosis (MS) are beginning to expire, opening the possibility of development, regulatory approval, and marketing of so-called follow-on biologics, biosimilars, or subsequent entry biologics that might be offered at lower price to consumers and third-party payers, as has been the case for generic drugs. Determining the comparability of a follow-on biologic to its innovator product is more difficult than for small-molecule drugs because of the greater complexity of biologics and the possibility that manufacturing differences can introduce differences in biologic activity and immunogenicity that could result in unpredictable differences in safety or efficacy. We provide a perspective on issues surrounding development, regulatory approval, and potential use of follow-on biologics, with an emphasis on disease-modifying agents for MS.
Glossary
- CHMP=
- Committee for Medicinal Products for Human Use;
- EMEA=
- European Medicines Agency;
- FDA=
- Food and Drug Administration;
- MS=
- multiple sclerosis.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- The challenge of follow-on biologics for treatment of multiple sclerosis
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Glossary
- THE ECONOMIC PRESSURE TO DEVELOP FOBs
- THE REQUIREMENT FOR COMPARABILITY
- APPROVAL OF GENERIC DRUGS AND IMPLICATIONS FOR FOBs
- DIFFERENCES BETWEEN DRUGS AND BIOLOGICS THAT IMPACT DETERMINATION OF COMPARABILITY WITH INNOVATORS
- DEVELOPMENT OF REGULATIONS GUIDING REVIEW AND APPROVAL OF GENERIC DRUGS IN THE UNITED STATES; IMPLICATIONS FOR THE EXPEDITED DEVELOPMENT AND APPROVAL OF FOBs
- CHANGES IN MANUFACTURING PROCEDURES FOR A BIOLOGIC; IMPLICATIONS FOR EXPEDITED DEVELOPMENT AND APPROVAL OF AN FOB
- CONCLUSIONS AND IMPLICATIONS OF FOBs AND THEIR REGULATORY REVIEW FOR MS
- ACKNOWLEDGMENT
- DISCLOSURE
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
